Compare AbbVie Inc (ABBV) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Select Medical Holdings Corporation — how do they compare? AbbVie Inc trades at $254.14 (market cap $449.91B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: AbbVie Inc is far larger — about 219.5× Select Medical Holdings Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | SEM | |
|---|---|---|
Market Cap | $449.91B | $2.05B |
Sector | Health | Health |
52-Week High | $261.07 | $16.66 |
52-Week Low | $184.85 | $11.77 |
Enterprise Value | $513.38B | $5.01B |
Dividend Yield | 2.72% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day, with a bullish technical signal supported by oversold RSI readings. The company reported 2025 revenue of $5.45 billion and net income of $146.22 million, with a P/E ratio of 15.43 and P/S of 0.36 indicating reasonable valuation. Recent news highlights the completion of its acquisition by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share, finalized on June 30, 2026.
The acquisition at $16.50 per share, just below the current price, limits near-term upside, while ongoing legal investigations into the board's fiduciary duties pose governance risks. Analyst consensus is mixed with 35.71% buy ratings, but stagnant revenue and declining net income margins signal fundamental challenges. Investors should weigh the acquisition's finality against operational headwinds and shareholder litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
